Literature DB >> 25941589

Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy.

Eric R Lutz1, Heather Kinkead2, Elizabeth M Jaffee3, Lei Zheng4.   

Abstract

Single agent immunotherapy is effective against several cancers, but has failed against poorly immunogenic cancers, including pancreatic cancer. Evaluation of pancreatic tumors following treatment with an experimental vaccine (Lutz et al. Cancer Immunology Research 2014) suggests that vaccination primes the tumor microenvironment (TME) for checkpoint-inhibitor immunotherapy, and supports a new platform for evaluating checkpoint-inhibitors in poorly immunogenic cancers.

Entities:  

Keywords:  pancreatic cancer; tumor immunotherapy; tumor vaccines

Year:  2014        PMID： 25941589      PMCID： PMC4292514          DOI： 10.4161/21624011.2014.962401

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  20 in total

1.  Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.

Authors:  Marie-Caroline Dieu-Nosjean; Martine Antoine; Claire Danel; Didier Heudes; Marie Wislez; Virginie Poulot; Nathalie Rabbe; Ludivine Laurans; Eric Tartour; Luc de Chaisemartin; Serge Lebecque; Wolf-Herman Fridman; Jacques Cadranel
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

Review 2.  Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma.

Authors:  Lei Zheng; Jing Xue; Elizabeth M Jaffee; Aida Habtezion
Journal:  Gastroenterology       Date:  2013-06       Impact factor: 22.682

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

4.  Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling.

Authors:  Domenico Coppola; Michael Nebozhyn; Farah Khalil; Hongyue Dai; Timothy Yeatman; Andrey Loboda; James J Mulé
Journal:  Am J Pathol       Date:  2011-05-03       Impact factor: 4.307

5.  Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.

Authors:  Richard E Royal; Catherine Levy; Keli Turner; Aarti Mathur; Marybeth Hughes; Udai S Kammula; Richard M Sherry; Suzanne L Topalian; James C Yang; Israel Lowy; Steven A Rosenberg
Journal:  J Immunother       Date:  2010-10       Impact factor: 4.456

6.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

7.  Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials.

Authors:  E M Jaffee; M Schutte; J Gossett; L A Morsberger; A J Adler; M Thomas; T F Greten; R H Hruban; C J Yeo; C A Griffin
Journal:  Cancer J Sci Am       Date:  1998 May-Jun

8.  Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.

Authors:  Dung T Le; Eric Lutz; Jennifer N Uram; Elizabeth A Sugar; Beth Onners; Sara Solt; Lei Zheng; Luis A Diaz; Ross C Donehower; Elizabeth M Jaffee; Daniel A Laheru
Journal:  J Immunother       Date:  2013-09       Impact factor: 4.456

9.  Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation.

Authors:  Eric R Lutz; Annie A Wu; Elaine Bigelow; Rajni Sharma; Guanglan Mo; Kevin Soares; Sara Solt; Alvin Dorman; Anthony Wamwea; Allison Yager; Daniel Laheru; Christopher L Wolfgang; Jiang Wang; Ralph H Hruban; Robert A Anders; Elizabeth M Jaffee; Lei Zheng
Journal:  Cancer Immunol Res       Date:  2014-06-18       Impact factor: 11.151

10.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Authors:  Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245
View more
  17 in total

1.  Rekindling cancer vaccines.

Authors:  Malorye Allison Branca
Journal:  Nat Biotechnol       Date:  2016-10-11       Impact factor: 54.908

Review 2.  Dendritic cell-based vaccine for pancreatic cancer in Japan.

Authors:  Masato Okamoto; Masanori Kobayashi; Yoshikazu Yonemitsu; Shigeo Koido; Sadamu Homma
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

3.  Actionable Intelligence Provided by Pancreatic Cancer Genomic Landscape: Are Targets for Curative Therapy On The Map?

Authors:  Nathan A Berger
Journal:  Transl Cancer Res       Date:  2016-08       Impact factor: 1.241

Review 4.  Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy.

Authors:  Krishna Patel; Sohail Siraj; Chloe Smith; Maya Nair; Jamboor K Vishwanatha; Riyaz Basha
Journal:  Crit Rev Oncog       Date:  2019

Review 5.  Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors.

Authors:  Jennifer Kleponis; Richard Skelton; Lei Zheng
Journal:  Cancer Biol Med       Date:  2015-09       Impact factor: 4.248

6.  Cancer-FOXP3 directly activated CCL5 to recruit FOXP3+Treg cells in pancreatic ductal adenocarcinoma.

Authors:  X Wang; M Lang; T Zhao; X Feng; C Zheng; C Huang; J Hao; J Dong; L Luo; X Li; C Lan; W Yu; M Yu; S Yang; H Ren
Journal:  Oncogene       Date:  2016-12-19       Impact factor: 9.867

Review 7.  Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.

Authors:  Derya Kabacaoglu; Katrin J Ciecielski; Dietrich A Ruess; Hana Algül
Journal:  Front Immunol       Date:  2018-08-15       Impact factor: 7.561

Review 8.  Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment.

Authors:  Chin-King Looi; Felicia Fei-Lei Chung; Chee-Onn Leong; Shew-Fung Wong; Rozita Rosli; Chun-Wai Mai
Journal:  J Exp Clin Cancer Res       Date:  2019-04-15

Review 9.  Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer.

Authors:  Jiajia Zhang; Christopher L Wolfgang; Lei Zheng
Journal:  Cancers (Basel)       Date:  2018-01-30       Impact factor: 6.639

Review 10.  Pancreatic cancer microenvironment: a current dilemma.

Authors:  Burak Uzunparmak; Ibrahim Halil Sahin
Journal:  Clin Transl Med       Date:  2019-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.